TheStreet Downgrades Astrazeneca PLC (AZN) to Hold
Astrazeneca PLC (NYSE:AZN) was downgraded by analysts at TheStreet to a “hold” rating in a note issued to investors on Friday.
Other research analysts have also recently issued research reports about the stock. Shore Capital reissued a “hold” rating on shares of Astrazeneca PLC in a report on Wednesday, July 27th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Astrazeneca PLC in a report on Monday, August 8th. Deutsche Bank AG reissued a “buy” rating on shares of Astrazeneca PLC in a report on Monday. Argus assumed coverage on Astrazeneca PLC in a research note on Tuesday, July 12th. They issued a “hold” rating for the company. Finally, Citigroup Inc. reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Wednesday, July 27th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. Astrazeneca PLC presently has a consensus rating of “Hold” and a consensus target price of $37.56.
Astrazeneca PLC (NYSE:AZN) traded down 0.62% on Friday, reaching $30.65. 668,596 shares of the company traded hands. Astrazeneca PLC has a one year low of $26.97 and a one year high of $35.04. The stock has a market capitalization of $77.54 billion, a PE ratio of 35.03 and a beta of 0.75. The firm has a 50 day moving average of $32.95 and a 200-day moving average of $30.86.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/14/thestreet-downgrades-astrazeneca-plc-azn-to-hold.html
Astrazeneca PLC (NYSE:AZN) last posted its earnings results on Thursday, July 28th. The company reported $0.83 EPS for the quarter, topping analysts’ consensus estimates of $0.76 by $0.07. The firm earned $5.60 billion during the quarter, compared to analysts’ expectations of $5.56 billion. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The business’s revenue for the quarter was down 4.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.21 earnings per share. On average, analysts anticipate that Astrazeneca PLC will post $2.97 EPS for the current year.
Institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. boosted its position in shares of Astrazeneca PLC by 0.3% in the first quarter. JPMorgan Chase & Co. now owns 2,325,462 shares of the company’s stock worth $65,485,000 after buying an additional 6,027 shares in the last quarter. Integrated Investment Consultants LLC boosted its position in shares of Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock worth $144,000 after buying an additional 275 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of Astrazeneca PLC by 3.1% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 34,217 shares of the company’s stock worth $964,000 after buying an additional 1,027 shares in the last quarter. Fisher Asset Management LLC boosted its position in shares of Astrazeneca PLC by 45.2% in the second quarter. Fisher Asset Management LLC now owns 338,979 shares of the company’s stock worth $10,159,000 after buying an additional 105,570 shares in the last quarter. Finally, Garrison Financial Corp boosted its position in shares of Astrazeneca PLC by 1.1% in the second quarter. Garrison Financial Corp now owns 18,992 shares of the company’s stock worth $573,000 after buying an additional 205 shares in the last quarter. Institutional investors own 11.39% of the company’s stock.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.